These studies describe the detection of a haptoglobin species, its characterization as the HPR gene product, and its association with both pregnancy and neoplasia. Previous work showed that the early recurrence of human breast cancer correlated with immunohistochemical staining with a commercial antiserum ostensibly directed against pregnancy-associated plasma protein A (PAPP-A). Use of this antiserum to guide purification ofthe putative antigen led to the present identification and purification of a strongly immunoreactive protein species distinct from PAPP-A that was present in the plasma of pregnant women at term. Unlike PAPP-A, a homotetramer of 200-kDa polypeptides, the immunoreactive protein consists of a light (a) chain (16.5 kDa) and a heavy (J6) chain (40 kDa); protein microsequencing of the 1 chain showed it to be a member of the haptoglobin family. The a chain of this haptoglobin species differs from ordinary haptoglobin 1 and 2 a chains both structurally and immunologically and represents the product of the HPR gene, haptoglobin-related protein (Hpr), since (i) the apparent molecular mass is the same as that predicted for Hpr a chain, (ii) the peptide map differs from that of haptoglobin 1 in a manner predicted by the HPR nucleotide sequence, (iii) monospecific antibodies that react with epitopes shared by the unique a chain and a synthetic peptide derived from the HPR nucleotide sequence do not detect these epitopes in either haptoglobin 1 or 2, and (iv) sequences of a-chain peptides were consistent with this identification, excluding haptoglobin 1 but not haptoglobin 2. The immunohistochemical reactivity of antibodies raised to the synthetic Hpr peptide is similar to that of anti-PAPP-A.
The present studies describe the expression of haptoglobinrelated protein (Hpr), the product of the HPR gene, and its association with both pregnancy and neoplasia. Conventional haptoglobins (Hps) have been well studied; the three known alleles each code for a precursor containing both the a and p8 chains (1) (2) (3) . Maeda (4) described the HPR locus as a stretch of DNA located 2.2 kilobases downstream from the conventional HP locus. This sequence appears to be an intact gene coding for a theoretical protein whose a and f8 chains are distinct from, but highly homologous to, conventional Hps, particularly haptoglobin 1 (Hp-1). Nevertheless, several investigators failed to detect Hpr expression (4) (5) (6) . Interestingly, the locus contains a retrovirus-like element and is duplicated in some individuals (4, 5) .
Experiments directly leading to the present studies found that a commercial antiserum to pregnancy-associated plasma protein A (PAPP-A) reacted immunohistochemically with human breast carcinomas and that those breast carcinomas staining positively for the antigen showed an increased propensity for tumor invasion and early metastasis. Clinically, these properties manifested as a dramatically worsened prognosis (7) (8) (9) . In Western blots (immunoblots) of fractions of sera from pregnant women, this antiserum detected a set of proteins whose properties were inconsistent with those of PAPP-A, a homotetramer composed of 200-kDa polypeptides. The studies below describe the purification of the unexpectedly immunoreactive protein species from the plasma ofpregnant women, its identification as the HPR gene product, and its relationship to the clinically important antigen expressed in human breast carcinoma.
MATERIALS AND METHODS
Patient Material. Term maternal plasma was obtained from discarded EDTA-anticoagulated whole blood samples from the delivery suite of The Johns Hopkins Hospital and stored at -70'C until use. Paraffin-embedded human breast carcinoma specimens were obtained from the Department of Pathology.
Electrophoresis and Western Blotting. NaDodSO4/polyacrylamide gel electrophoresis used the Laemmli system (10). For Western blotting, Laemmli gels were transferred to 0.45-,um nitrocellulose sheets (Schleicher & Schuell) in 96 mM glycine/12.5 mM Tris/0.1% NaDodSO4/20% (vol/vol) methanol at 40 V, 250-300 mA, at 40C for 6 Peptide Mapping. Peptide mapping was performed using the Elder technique (13, 14) .
Preparation of Anti-Hpr Antibody. A synthetic peptide corresponding to the 34 N-terminal residues of the predicted HPR gene product (4) was synthesized by the Protein Chemistry Facility on an Applied Biosystems model 43A peptide synthesizer (15) . Because histidine coupling is inefficient, lysine was conservatively substituted for the histidine in position 28 . For immunization, the peptide was conjugated to keyhole limpet hemocyanin (KLH) (Boehringer Mannheim) essentially as described (16) . The To purify the antibody, a 10 cm x 5 mm SelectiSpher-10 activated-tresyl HPLC affinity column (Pierce) was derivatized with the Hpr synthetic peptide. The column was washed with 30 ml of PBS at 2 ml/min, then 27 mg of peptide dissolved in 4.5 ml of PBS was applied at a rate of 1 ml/min. Unreacted tresyl groups were capped with 30 ml of 0.2 M Tris HCI (pH 8.0) through the column. For antibody purification, the column was equilibrated in 300 mM NaCI/20 mM sodium phosphate, pH 7.5. Serum (10-20 ml) was loaded at 0.5 ml/min. After loading, the column was washed with buffer until the 0D280 of the effluent returned to zero. Antibody was eluted with 6 M urea in the same buffer, and the antibody-containing fractions were immediately dialyzed into Tris-buffered saline with 1 mM NaN3. buffer. The Hpr peptide column was then denatured with 100 ml of 0.1% NaDodSO4 in Tris/saline buffer.
Monospecific anti-Hpr antibodies were isolated from the crude anti-PAPP-A serum by sequential affinity chromatographic steps. First, 100 A.l of crude anti-PAPP-A antibody in 10 ml of Tris/saline buffer was incubated with the Hp-1 gel overnight at 40C with agitation. The gel was next washed extensively with Tris/saline and the flow-through was collected over a 5-ml hydroxyapatite column. Antibodies that bound to the Hp-1 column were eluted with 20 ml of acetate buffer (0.05 M sodium acetate/0.15 M NaCl, pH 3.5, at room temperature). The antibodies that flowed through the column were eluted from the hydroxyapatite column with 20 ml of 0.4 M sodium phosphate. Both sets of antibodies were dialyzed against 2 liters of Tris/saline buffer.
The antibodies that did not bind to the Hp-i column were then incubated with the denatured Hpr peptide gel overnight at 4°C with agitation. Antibodies that bound to the Hpr peptide were eluted with 20 ml of acetate buffer and dialyzed against Tris/saline. Immunohistochemistry. Immunohistochemistry was performed using the unlabeled antibody immunoperoxidase technique for formalin-fixed paraffin-embedded tissues (7) .
RESULTS

Purification of Immunoreactive Proteins from Pregnancy
Serum. The initial goal was to characterize the substance in human breast carcinoma that reacted with the crude IgG fraction of a commercially produced antiserum to PAPP-A. as a separate, albeit overlapping peak, the 40-kDa species co-eluting with a strongly immunoreactive 16.5-kDa band.
The relationship between the purified protein and the immunoreactive material in breast cancer was explored using a human breast carcinoma known to stain positively both with anti-PAPP-A and with anti-carcinoembryonic antigen (CEA). Preincubation of anti-PAPP-A with a mixture of the purified protein species ablated immunostaining, but preincubation of anti-CEA under similar conditions had no effect, thus demonstrating an immunologic relationship between the material present in breast cancer and that found in pregnancy serum (data not shown).
Identification as a Hp by Protein Microsequencing. The 40-kDa chain was isolated by anion-exchange HPLC under denaturing conditions. N-terminal sequencing yielded 20 residues. Using the protein sequence data base of the National Biomedical Research Foundation (November 1987) and the DFASTP alignment program, three protein sequences showed 100% homology over the entire 20-amino acid stretch with the chain of human Hp-i, the 8 chain of human haptoglobin 2 (Hp-2), and the predicted ,8 chain of the Hpr precursor (6, (18) (19) (20) (21) Fig. 2 shows the results of an immunologic analysis performed with purified Hp-i and -2 standards, the Hp purified from pregnancy serum, rabbit anti-Hp, and anti-PAPP-A. Fig. 2A shows a 10-15% polyacrylamide Coomassie blue-stained Laemmli and distribution, recognizing all three Hp chains; the relative immunoreactivity of the 16.5-kDa chain of the purified protein is commensurate with the relative intensity of its Coomassie blue staining. Anti-PAPP-A also reacts with Hp heavy chains and Hp-2 light chain; however, its relative immunoreactivity with the 16.5-kDa chain from pregnancy serum shown in lane c is disproportionately intense in comparison to its Coomassie blue staining, particularly when compared to the disproportionately weak relative immunoreactivity of the Hp-1 a chain shown in lane a. Thus, the a chain isolated from pregnancy plasma is immunologically distinct, containing epitopes seen by the anti-PAPP-A that are not present in the a chains of either Hp-1 or Hp-2.
In addition to immunologic analysis, peptide mapping (13, 14) was performed to identify potential structural differences between heavy and light chains from the Hps and purified pregnancy protein. Peptide mapping by this technique detects only tyrosine-containing peptides. Using the published amino acid sequences, the family of tryptic peptides from the a chains of Hp-1 and Hp-2 should each be similar since Hp-2 resulted from a partial reduplication of Hp-1 (1) (Fig. 3 A and  C) . The principal differences in amino acid sequence of Hpr, Hp-1, and Hp-2 lie in the a chains. Within the a chains, these differences cluster principally at the N termini. The deduced Hpr a-chain sequence predicts the same tryptic peptides as obtained from Hp-1 plus one additional tyrosine-containing peptide. Fig. 3B shows the peptide map ofthe purified a chain from the pregnancy-associated protein with an arrow highlighting the one additional peptide obtained experimentally. These results thus raise the possibility that the Hp purified from pregnancy plasma might represent the HPR gene product. Fig. 3D Fig. 4 shows, by stepwise immunoselection, that the antibodies that react to the a chain of the Hp from pregnancy serum also react with the Hpr synthetic peptide. was incubated with unabsorbed anti-PAPP-A serum, and, as in Fig. 2C , there is scant reactivity to the Hp-1 a chain, weak reactivity to the contaminating 20-kDa Hp-2 a chain, but intense labeling of the 16.5-kDa pregnancy-associated Hp a chain along with the 40-kDa ,1 chains. Fig. 4 co-migrating on Laemmli gels with the Hp-1 a chain; (iii) the peptide map of the purified a chain differs from the maps of the a chains of Hp-1 and Hp-2 in the manner that would be predicted from the Hpr a-chain sequence; and (iv) the Hpr a chain co-purifies with a second polypeptide chain whose size and N-terminal amino acid sequence are consistent with those of Hp p chains. Additional support comes from sequencing. Unfortunately, the N terminus of the purified Hpr a chain is blocked, and attempts to isolate enzymatically cleaved peptides from the N-terminal portion of the molecule were unsuccessful. Two peptides, Gly-Lys-Pro-Lys-Asn-Pro-AlaAsn-Gln-Val-Gln-Arg and Thr-Leu-Asn-Asp-Lys-Lys-GluTrp, were isolated whose sequences are common to Hpr and Hp-2 a chains, but are not contained in the sequence of the Hp-1 a chain. In view of the other data, including high molar yields of these peptides and the absence of any detectable contaminating Hp-2, it is most likely that these peptides are derived from the a chain of Hpr.
Hps are acute-phase proteins initially discovered by their ability to bind hemoglobin, enhancing the endogenous peroxidase activity of hemoglobin (1-3) . Traditionally, Hp function has been thought principally to be iron conservation mediated by its ability to bind hemoglobin. Hps would thus prevent renal excretion of free hemoglobin and recycle iron to the liver by a hepatocyte cell surface receptor for the Hphemoglobin complex (23) (24) (25) (26) ; additionally, by binding iron, they might also exert an antibacterial effect (27) . The present data suggest additional possibilities. (35) . As the comparison between neoplastic states and pregnancy is often drawn, Hpr may subsume similar functions in pregnancy and neoplasia, aiding development in one instance while facilitating tumor invasion and metastasis in the other.
